Compass Pathfinder Limited

COMPASS Pathways plc is a biotechnology company headquartered in London, United Kingdom, dedicated to accelerating patient access to evidence-based innovation in mental health. The company's core mission is to reimagine mental health care by developing psychedelic medicines to address the significant unmet needs of individuals suffering from mental health conditions for which current treatments are insufficient.

COMPASS Pathways' primary focus is on its investigational COMP360 psilocybin treatment, which is currently in late-stage clinical trials, specifically Phase 3, for treatment-resistant depression (TRD). This proprietary synthetic psilocybin formulation is administered in conjunction with psychological support and has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. The company is also exploring COMP360 for other mental health conditions, including post-traumatic stress disorder (PTSD) and anorexia nervosa.

In recent developments, COMPASS Pathways announced in April 2026 that the FDA granted a New Drug Application (NDA) rolling review request and awarded a Commissioner's National Priority Voucher for COMP360 in TRD, which could expedite the review process. The company has also engaged in collaborations with organizations like Osmind and Mindful Health Solutions to inform the development of scalable delivery models for COMP360, if approved. Kabir Nath serves as the Chief Executive Officer, leading the company's efforts to bring this potential transformative treatment to patients.